Cataract – Pipeline Review, 2024

Cataract is a disorder that causes blurring of the vision. It is commonly identified in elder patients as a result of ageing. Other causes may also include injury to tissue of eye lens, medical conditions such as diabetes or long term use of steroids. Cataract are classified as nuclear cataract, cortical cataract, posterior sub-capsular cataract and congenital cataract. Symptoms that are observed in patients with cataract are clouded or dim vision, poor vision at night, sensitivity to light, and occurrence of double vision in single eye.

Current treatment for cataract includes use of eye glasses, anti-glare glasses or lenses. These treatments are provided to improve the symptoms of cataract. However, if the condition worsens, surgery is an effective treatment.

Research Institutes and pharmaceutical companies have focussed on studying and developing new methods for the treatment of cataract. For instance; RX-10045, is being studied by A.T. Resolve SARL, is currently in phase 2 of a clinical trial for the study to evaluate its safety and efficacy in patients with ocular inflammation and pain while undergoing a cataract surgery. OMS302, which is being studied by Omeros Corporation, to evaluate its safety and efficacy in patients undergoing cataract extraction with lens replacement (CELR) and is currently in phase 3 of clinical trial.

Currently, more than 50% of the pipeline candidates for cataract are in phase 2 and phase 3 of clinical trials. Majority of the studies have been sponsored by research institutes.

Report Description

The report on ‘Cataract – Pipeline Review, 2024’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for cataract. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for cataract.

The report on ‘Cataract– Pipeline Review, 2024’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for cataract


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for cataract


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary